Search the Newsreel

Is BioMarin Pharmaceutical (BMRN) Still Cheap As 2026 Guidance Rises And Amicus Adds Growth?

BioMarin Pharmaceutical (BMRN) has updated its 2026 guidance and completed the Amicus acquisition, leading to increased attention on the stock. Despite strong short-term momentum and a "22% Undervalued" narrative, the article highlights the need for investors to consider inherent risks, such as reliance on …

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is BioMarin Pharmaceutical (BMRN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector …

Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries

For Immediate Release Chicago, IL – August 14, 2026 – Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different …

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. …

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the morning session after an analyst at Canaccord Genuity raised the company's price target to $114 from $111 and maintained a …

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth

Key Points Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better. BioMarin raised its financial outlook after second-quarter revenue approached $1 billion, lifting 2025 revenue guidance to $3.875 billion–$3.925 billion and non-GAAP EPS guidance to $4.90–$5.10. The Amicus acquisition added Galafold …

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by Analysts

Analysts have given BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) an average "Moderate Buy" rating, with a consensus 12-month price target of $88.00. The company recently reported strong quarterly results, with revenue up 20% year-over-year and raised its 2026 VOXZOGO revenue guidance to at least $1 billion. …

BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History

Biomarin Pharmaceutical stock hits 52-week high at 66.28 USD

BioMarin Pharmaceutical (BMRN) stock reached a new 52-week high of $66.28, reflecting a 16.44% increase over the past year. InvestingPro analysis suggests the stock is undervalued with strong fundamentals, including 11.2% revenue growth. The company also reported impressive Q2 2026 results, exceeding Wall Street …

BioMarin Pharmaceutical Aktie erreicht 52-Wochen-Hoch bei 66,28 USD

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.BioMarin Pharmaceutical logo An audio webcast of the presentation …

BioMarin presentation to stream live from Boston on Aug. 12

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced it will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00 AM ET in Boston. A live audio webcast and a limited-time archived replay will be available on the company's investor …

Canaccord raises BioMarin stock price target on revenue growth

Canaccord has increased its price target for BioMarin Pharmaceutical Inc. (BMRN) to $114 from $111, maintaining a Buy rating, following strong second-quarter 2026 earnings. The company's revenue growth was significantly boosted by the acquisition of GALAFOLD and POMBILITI + OPFOLDA, leading to raised fiscal …

BioMarin (BMRN) Is Up 6.3% After Raising 2026 Revenue Guidance And Highlighting Voxzogo Momentum

BioMarin Pharmaceutical Inc. (BMRN.MX) Analyst insights, Price targets and Recommendations

This article provides an overview of recent analyst ratings for BioMarin Pharmaceutical Inc. (BMRN.MX), including upgrades, downgrades, and maintained ratings from various financial institutions. It lists the latest price targets and recommendations from firms like Morgan Stanley, Oppenheimer, and Citigroup, along with the dates …

BioMarin Pharmaceutical Inc. Stock 12‑Month Price Target Raised to $89.5, Implies 46% Upside

BioMarin Pharmaceutical Inc.'s average stock price target has been raised to $89.5 from $87.83 by 24 analysts, indicating a potential 46% upside based on the Aug. 6 closing price. The consensus rating from 29 analysts remains "Buy," with 22 Buys, 7 Holds, and no …

BioMarin (BMRN) Stock Gains On Higher Outlook Despite Profit Drop

BioMarin Pharmaceutical Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BMRN) 2026-08-07

BioMarin Pharmaceutical's Q2 revenue approached $1 billion, a 20% increase year-over-year, driven by its rare-disease portfolio and the Amicus acquisition. The company raised its full-year guidance for revenue, VOXZOGO revenue, and non-GAAP EPS, projecting significant growth from Amicus therapies and VOXZOGO becoming a $1 …

BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

BioMarin Pharmaceutical Inc (BMRN) Aktuelle Aktien-News

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) News, Articles, Events & Latest Updates

BioMarin Pharmaceutical Inc. (BMRN) has reported strong Q2 2026 earnings, surpassing estimates in both revenue and profit, driven by significant sales growth and an increased 2026 outlook. The company also announced an early research collaboration with n-Lorem Foundation and the FDA's acceptance of its …

BioMarin Pharmaceutical Inc (BMRN) (Q2 2026) Earnings Call Highlights: Record Revenue and ...

BioMarin Pharmaceutical (BMRN) Could Be 30% Below Fair Value On Raised Guidance

Biomarin Pharma earnings beat by $0.25, revenue topped estimates

Biomarin Pharma (NASDAQ: BMRN) reported strong second-quarter results, beating analyst estimates for both earnings per share (EPS) and revenue. The company posted an EPS of $1.20, exceeding the $0.95 consensus, and revenue of $990 million, higher than the $939.37 million estimate. Its stock has …

Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics

Informe de resultados de BioMarin Q2 2026: supera previsiones y mejora perspectivas

BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates

BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Impressive Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations

BioMarin Pharmaceutical: Non-GAAP-Gewinn je Aktie sinkt im Q2, Umsatz steigt; Prognose für 2026 angehoben

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Q2 revenue up, profit down after Amicus acquisition

BioMarin Pharmaceutical Inc. reported a significant increase in Q2 2026 total revenues to $989.7 million, up from $825.4 million in 2025, primarily due to strong performance from VOXZOGO, PALYNZIQ, and newly acquired products GALAFOLD and POMBILITI + OPFOLDA. Despite revenue growth, net income fell …

BIOMARIN PHARMACEUTICAL ($BMRN) Releases Q2 2026 Earnings, Stock Rises

BioMarin Pharmaceutical Inc. presenta sus previsiones de resultados para el tercer y cuarto trimestre de 2026

Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q2 Adjusted EPS $1.20 per Share, vs. FactSet Est of $0.95

BioMarin Pharmaceutical Inc. (BMRN) reported Q2 adjusted EPS of $1.20 per share, surpassing the FactSet estimate of $0.95. The company also announced Q2 revenue of $990.0 million, exceeding the FactSet estimate of $932.0 million, and provided updated earnings guidance for the full year 2026. …